Skip to main content
SCTX
NASDAQ Life Sciences

Scribe Posts Q3 Loss of $9.9M; $174.2M Cash Funds Operations Into 1H 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$16.99
Mkt Cap
$321.649M
52W Low
$13.5
52W High
$39.6
52W Position info
26% above low
Off High info
57% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SCTX sits 26% above its 52-week low of $13.5.

Summary

Scribe reported a $9.9 million Q3 net loss and $174.2 million in cash that funds operations into the first half of 2029; STX-1150 Phase 1 data are now expected in 1H 2027.


Key Events · Earnings and Guidance · SCTX

  • Q3 Net Loss Widens to $9.9M

    Net loss was $9.9 million, or $0.68 per basic and diluted share, versus $6.5 million in Q2 2026, as G&A rose to $4.2 million from $2.5 million on public-company costs and stock compensation.

  • Cash of $174.2M Funds Into 1H 2029

    Cash, cash equivalents and marketable securities stood at $174.2 million at September 30, 2026, up from $43.0 million at June 30, 2026, primarily on roughly $140.2 million of net IPO and concurrent private placement proceeds.

  • Revenue Slips on Lower Lilly Activity

    Collaboration revenue was $1.6 million for Q3 2026 versus $1.9 million in Q2 2026, attributed to lower reimbursable R&D under the Eli Lilly collaboration.

  • STX-1150 Phase 1 Data Due 1H 2027

    The first-in-human Phase 1 trial of STX-1150 continues enrolling; initial single-ascending-dose safety and LDL-C lowering data are expected in the first half of 2027.


Analysis · SCTX · Life Sciences

The cash pile from the July IPO is the headline here: $174.2 million at September 30 versus $43.0 million at June 30, enough to fund operations into the first half of 2029. That removes any near-term financing need, and the going-concern doubt disclosed for June 30 is now a resolved historical item. The offset is a wider loss — $9.9 million in Q3 versus $6.5 million in Q2 — driven by G&A jumping to $4.2 million from $2.5 million as public-company costs and stock compensation kick in, while collaboration revenue slipped to $1.6 million from $1.9 million on lower Lilly reimbursable activity. On the pipeline, the readout that matters is STX-1150 Phase 1 data, now guided to the first half of 2027, so there is no clinical catalyst in the near term. The Sanofi expansion to include ELXR silencing technology adds a second technology licensed to an existing partner but carries no disclosed new dollar amount.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SCTX was trading at $16.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $321.6M. The 52-week trading range was $13.50 to $39.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SCTX - Latest Insights

SCTX
Sep 02, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.90
Real-time Price: $16.49 info
Change: -$14.41 (-47%) info
Market Cap: $309.722M info
SCTX
Sep 02, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.90
Real-time Price: $16.49 info
Change: -$14.41 (-47%) info
Market Cap: $309.722M info
SCTX
Jul 30, 2026, 9:30 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $22.46
Real-time Price: $16.49 info
Change: -$5.97 (-27%) info
Market Cap: $309.722M info
SCTX
Jul 30, 2026, 4:39 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $23.00
Real-time Price: $16.49 info
Change: -$6.51 (-28%) info
Market Cap: $309.722M info
SCTX
Jul 29, 2026, 7:09 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $18.50
Real-time Price: $16.49 info
Change: -$2.01 (-11%) info
Market Cap: $309.722M info